Please login to the form below

Not currently logged in
Email:
Password:

FDA approves Pfizer's pain drug

Pfizer has announced that the US Food and Drug Administration has approved its drug Oxecta for use in the management of acute and chronic moderate to severe pain

Pfizer has announced that the US Food and Drug Administration (FDA) has approved its drug Oxecta (oxycodone) for use in the management of acute and chronic moderate to severe pain where the use of an opioid analgesic is appropriate.

Oxecta makes use of a technology that is designed to discourage methods of drug tampering associated with abuse of opioids. Pfizer has licensed the technology from Acura, a pharma company specialising in developing product candidates to potentially deter abuse and misuse.

Opioid analgesics such as Oxecta are prescribed for patients whose condition isn't managed by other pain treatments, but can result in overdose and death if abused.

Speaking on the approval, Olivier Brandicourt, Pfizer president and general manager, Primary Care, said: "We recognise our responsibility to physicians and patients and remain committed to appropriate access to pain treatment and developing medicines to potentially address this important public health and safety issue."

Oxecta was originally developed by King Pharmaceuticals. Pfizer acquired the drug when it purchased King in late 2010.

21st June 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Dovetail

We're award-winning joint working specialists. We help our clients to transform healthcare through effective collaboration, and deliver work to feel...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics